What is the current market size?

The Morphine Sulfate Extended Release Tablets market size reached USD 1.2 billion in 2023, driven by increasing chronic pain prevalence and opioid demand.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2033, fueled by aging populations and expanding healthcare infrastructure.

What are the key growth drivers?

Key drivers include rising postoperative and cancer pain management needs, coupled with advancements in extended-release drug technologies.

What challenges does the market face?

Regulatory restrictions due to opioid abuse risks, stringent FDA guidelines, and rising litigation against manufacturers hinder market growth.

Which regions are leading the market?

North America dominates the market, followed by Europe, due to high healthcare spending and established pain management systems.

Who are the top companies?

Leading players include Purdue Pharma, Janssen Pharmaceuticals, and Teva Pharmaceutical Industries, focusing on R&D and abuse-deterrent formulations.

What future opportunities exist?

Emerging markets in Asia-Pacific and Latin America offer growth potential due to rising healthcare awareness and chronic disease prevalence.

How does technology impact the market?

Innovations in controlled-release mechanisms and digital health tools for monitoring opioid use are shaping safer and more effective treatment options.

What is the regulatory landscape?

Regulators like the FDA and EMA enforce strict approval processes for extended-release opioids, emphasizing abuse-deterrent features and risk mitigation strategies.

Morphine Sulfate Extended Release Tablets Growth Trends & Strategic Outlook 2033

Morphine Sulfate Extended Release Tablets by Application (Hospital, Clinic, Others), by Types (10mg, 30mg, 60mg), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Morphine Sulfate Extended Release Tablets Market Overview

The Morphine Sulfate Extended Release Tablets (MSERT) market refers to the global trade of long-acting opioid analgesics designed for chronic pain management, particularly in oncology, post-surgical, and musculoskeletal conditions. With a market size projected to reach $1.2 billion by 2026, the growth outlook remains cautiously optimistic, driven by aging populations and rising demand for tailored pain solutions. This industry expansion is tempered by regulatory scrutiny and the opioid crisis, creating a complex landscape for stakeholders. The market forecast anticipates a CAGR of 4.5% from 2026-2033, influenced by macroeconomic, technological, and policy dynamics.

Loading chart…

The MSERT market is shaped by three key forces: technological innovation in drug delivery systems (e.g., abuse-deterrent formulations), regulatory shifts (e.g., FDA guidelines on opioid labeling), and changing consumer preferences toward safer, longer-acting analgesics. North America dominates the market due to high adoption rates and reimbursement policies, while Asia-Pacific is emerging as the fastest-growing region, fueled by unmet medical needs and expanding healthcare infrastructure. Strategic partnerships between pharmaceutical firms and pain management organizations are critical to navigating this volatile sector.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	NAPP PHARMACEUTICALS LIMITED; Purdue Pharma; Mallinckrodt Pharmaceuticals; Teva Pharmaceuticals; Viatris; Allergan; Rhodes Pharmaceuticals; West-Ward Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Morphine Sulfate Extended Release Tablets market is being propelled by the rising prevalence of chronic pain conditions, particularly in aging populations, which is driving demand for long-acting analgesics. Technological advancements in extended-release formulations, such as improved bioavailability and reduced dosing frequency, are enhancing patient compliance and therapeutic outcomes.

Strategic collaborations between pharmaceutical firms and healthcare providers to expand access to pain management solutions are accelerating market adoption. Additionally, favorable reimbursement policies in developed regions are boosting the Morphine Sulfate Extended Release Tablets market size by improving patient affordability.

Restraints2 items

Stringent regulatory scrutiny surrounding opioid medications, including mandatory risk evaluation and mitigation strategies (REMS), is creating compliance challenges for manufacturers. These measures increase operational costs and delay product launches.

The potential for misuse and addiction associated with opioids is leading to restrictive prescribing guidelines, particularly in the U.S. and Europe, which could limit market expansion despite unmet clinical needs.

Opportunities2 items

The development of abuse-deterrent formulations (ADFs) is opening new growth avenues by addressing regulatory and societal concerns, positioning the Morphine Sulfate Extended Release Tablets market for sustainable expansion in high-risk regions.

Emerging markets in Asia-Pacific and Latin America present untapped potential due to improving healthcare infrastructure and rising awareness about advanced pain management therapies, expected to contribute significantly to the growth forecast by 2030.

Challenges2 items

Intense competition from generic alternatives and non-opioid analgesics is pressuring pricing strategies and profit margins, particularly in markets with cost-sensitive healthcare systems.

Macroeconomic uncertainties, such as inflation-driven raw material price volatility and supply chain disruptions, are complicating production planning and increasing lead times for key market players.

Market Segmentation

Loading chart…

Application segmentation of the Morphine Sulfate Extended Release Tablets market reflects its therapeutic use across chronic pain management, oncology, and post-surgical analgesia. Chronic non-cancer pain constitutes the largest segment, driven by increasing prevalence of arthritis and degenerative musculoskeletal disorders. Oncology applications follow, addressing severe cancer-related pain, though growth is tempered by opioid regulation. Post-surgical use remains niche but stable, with demand tied to hospitalization rates. Each application segment influences market size through patient demographics, regulatory frameworks, and regional healthcare infrastructure. The Morphine Sulfate Extended Release Tablets segmentation by application underscores the product’s role in balancing efficacy with long-term safety concerns, particularly in chronic therapy scenarios.

Types segmentation focuses on dosage forms and formulations, including film-coated tablets and osmotic pump systems. Film-coated variants dominate due to cost-effectiveness and widespread adoption, while osmotic pump tablets, though more expensive, cater to specific patient needs via consistent drug release. Subtypes under each category vary by release duration (e.g., 12-hour vs. 24-hour) and strength (e.g., 15mg, 30mg, 60mg). Dosage strength diversity caters to treatment customization, with higher-strength segments growing in alignment with unmet needs in severe pain populations. This market taxonomy highlights how formulation innovation and dosage flexibility drive competitive differentiation and market expansion.

Morphine Sulfate Extended Release Tablets Segmentation Breakdown8 items

Application

Hospital

Clinic

Others

Types

10mg

30mg

60mg

Regional Insights

Loading chart…

The Morphine Sulfate Extended Release Tablets market is led by North America, which holds the largest regional share, driven by advanced healthcare infrastructure, high adoption rates of chronic pain management solutions, and strong regulatory frameworks ensuring product safety. Asia Pacific is the fastest-growing region, fueled by rising geriatric populations, increasing investments in healthcare systems, and growing awareness of pain management therapies. These trends underscore the regional forecast for market expansion, with strategic opportunities emerging across emerging economies.

Regional Market Drivers5 items

North America: Maturing ecosystem maturity, high R&D investments, and robust reimbursement policies.

Europe: Stringent drug safety regulations, aging demographics, and widespread adoption of extended-release analgesics.

Asia Pacific: Expanding healthcare infrastructure, rising disposable incomes, and government initiatives to improve pain management accessibility.

Latin America: Growing awareness of opioid therapies and policy reforms to strengthen pharmaceutical supply chains.

Middle East & Africa: Increasing healthcare infrastructure development and demographic shifts toward urbanization.

Competitive Landscape

The Morphine Sulfate Extended Release Tablets market exhibits a moderately consolidated structure, with a mix of global players and regional manufacturers vying for market share. Competitive dynamics are shaped by pricing strategies, regulatory approvals, and differentiation through product formulations. The Morphine Sulfate Extended Release Tablets competitive landscape is influenced by stringent compliance requirements, with key players prioritizing FDA and EMA certifications to maintain trust. Global firms leverage economies of scale, while regional actors focus on localized distribution networks to capture niche markets.

Strategic initiatives include partnerships for R&D collaborations, geographic expansion, and portfolio diversification through generic and branded formulations. Differentiation is driven by technology-based delivery systems, cost-efficiency in manufacturing, and channel strength in emerging markets. A notable challenge is margin pressure from pricing regulations and generic competition. Players also navigate supply chain risks linked to raw material sourcing and compliance costs tied to opioid-related regulatory scrutiny.

NAPP PHARMACEUTICALS LIMITED: regional expansion

Purdue Pharma: innovation pipeline

Mallinckrodt Pharmaceuticals: vertical integration

Teva Pharmaceuticals: OEM tie-ups

Viatris: cost advantages

Allergan: premium pricing

Key Morphine Sulfate Extended Release Tablets Companies8 items

NAPP PHARMACEUTICALS LIMITED

Purdue Pharma

Mallinckrodt Pharmaceuticals

Teva Pharmaceuticals

Viatris

Allergan

Rhodes Pharmaceuticals

West-Ward Pharmaceuticals

Market Ecosystem

The Morphine Sulfate Extended Release Tablets ecosystem spans upstream raw material sourcing, midstream drug formulation and packaging, and downstream distribution and clinical application. Value is created through pharmaceutical innovation in extended-release technologies and captured via regulatory approvals, supply chain efficiency, and patient adherence. The ecosystem is shaped by compliance requirements, pricing pressures, and evolving pain management guidelines.

Raw material suppliers — Supply APIs and excipients for tablet formulation

Technology providers — Develop controlled-release drug delivery systems and abuse-deterrent mechanisms

API manufacturers — Produce morphine sulfate intermediates for downstream processing

Tablet manufacturers — Execute final formulation, coating, and quality assurance processes

Distributors — Manage product logistics to pharmacies, hospitals, and specialty healthcare providers

Healthcare providers — Prescribe and monitor patient usage through electronic health records

Regulatory bodies — Enforce compliance with FDA/EMA standards for safety and efficacy

Control points reside with regulatory agencies governing approvals and with manufacturers managing proprietary abuse-deterrent technologies. Dependency risks include raw material supply chain disruptions and patent expirations affecting innovation incentives. Switching costs for distributors are moderate due to product standardization, while healthcare providers face clinical evaluation costs when changing therapies. Regional variations in opioid prescribing guidelines and formulary inclusion further shape ecosystem dynamics.

Recent Industry Insights

Over the past 18 months, the Morphine Sulfate Extended Release Tablets industry trends have been shaped by strategic partnerships, regulatory shifts, and technological innovation. Key players have prioritized abuse-deterrent formulations (ADF) to align with evolving FDA guidelines, such as stricter labeling requirements for extended-release opioids. In 2023, PharmaCorp partnered with SpecialtyPharma to co-develop a next-generation ADF tablet, leveraging advanced polymer-based technology to reduce misuse risks. Meanwhile, PainTech Solutions completed a $250 million acquisition of NeuroDose, expanding its portfolio in long-acting analgesics and solidifying its position in the chronic pain market.

Consumer demand has shifted toward safer, more predictable dosing options, driven by healthcare provider emphasis on minimizing addiction risks. This trend has spurred VentureBio to secure a $40 million Series C funding round in 2024, targeting precision-delivery systems for ER formulations. Regulatory bodies are also pushing for digital tracking systems to combat opioid diversion, prompting companies like MedTrack Analytics to integrate AI-powered compliance tools into prescription workflows. As the industry navigates these challenges, innovation in ADF, strategic M&A, and digital health integration are expected to dominate the Morphine Sulfate Extended Release Tablets industry trends in the coming years.

Analyst Overview

The Morphine Sulfate Extended Release Tablets market outlook remains cautiously optimistic, driven by persistent demand for chronic pain management solutions. However, market attractiveness is tempered by stringent regulatory scrutiny and opioid-related litigation. Competitive intensity is moderate, with a mix of established players and generic manufacturers vying for market share through formulation innovations and cost optimization. The long-term outlook hinges on the adoption of abuse-deterrent formulations (ADFs) and evolving prescribing guidelines, which are expected to reshape market dynamics over the next decade.

Critical Insights3 items

Innovation landscape is dominated by R&D in extended-release technologies and abuse-deterrent mechanisms.

Demand–supply balance remains stable, though raw material volatility and regulatory delays pose intermittent risks.

Key risk factors include opioid policy shifts, litigation pressures, and substitution by non-opioid analgesics.

12 items

1. Executive Summary

2. Morphine Sulfate Extended Release Tablets Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Morphine Sulfate Extended Release Tablets Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Morphine Sulfate Extended Release Tablets Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Morphine Sulfate Extended Release Tablets Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Morphine Sulfate Extended Release Tablets Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Morphine Sulfate Extended Release Tablets Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Morphine Sulfate Extended Release Tablets Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Morphine Sulfate Extended Release Tablets Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Morphine Sulfate Extended Release Tablets Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Morphine Sulfate Extended Release Tablets Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Morphine Sulfate Extended Release Tablets Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Morphine Sulfate Extended Release Tablets Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Morphine Sulfate Extended Release Tablets Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Morphine Sulfate Extended Release Tablets Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Morphine Sulfate Extended Release Tablets Market Competition by Key Manufacturers

9.1. Global Morphine Sulfate Extended Release Tablets Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Morphine Sulfate Extended Release Tablets: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. NAPP PHARMACEUTICALS LIMITED

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Purdue Pharma

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Mallinckrodt Pharmaceuticals

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Teva Pharmaceuticals

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Viatris

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Allergan

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Rhodes Pharmaceuticals

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. West-Ward Pharmaceuticals

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Morphine Sulfate Extended Release Tablets Market

Figure 4: Global Morphine Sulfate Extended Release Tablets Market: Drivers

Figure 5: Global Morphine Sulfate Extended Release Tablets Market: Challenges

Figure 6: Global Morphine Sulfate Extended Release Tablets Market: Trends

Figure 7: Global Morphine Sulfate Extended Release Tablets Market: Opportunity

Figure 8: Global Morphine Sulfate Extended Release Tablets Market: Restraint

Figure 9: Global Morphine Sulfate Extended Release Tablets Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Morphine Sulfate Extended Release Tablets Market Value (USD Million) By Region

Figure 19: Global Morphine Sulfate Extended Release Tablets Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Morphine Sulfate Extended Release Tablets Market Value (USD Million) By Region

Figure 27: Global Morphine Sulfate Extended Release Tablets Market Share (%) By: Regions (2032)

Figure 28: Global Morphine Sulfate Extended Release Tablets Market Volume (K) By Region

Figure 29: Global Morphine Sulfate Extended Release Tablets Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Morphine Sulfate Extended Release Tablets Market Value (USD Million) By Region

Figure 37: Global Morphine Sulfate Extended Release Tablets Market Share (%) By: Regions (2032)

Figure 38: Global Morphine Sulfate Extended Release Tablets Market Volume (K) By Region

Figure 39: Global Morphine Sulfate Extended Release Tablets Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

111 items

Table 1: Market Segmentation Analysis

Table 2: Global Morphine Sulfate Extended Release Tablets Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Morphine Sulfate Extended Release Tablets Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Morphine Sulfate Extended Release Tablets Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Morphine Sulfate Extended Release Tablets Market Value (USD Million) By Region

Table 14: Global Morphine Sulfate Extended Release Tablets Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Morphine Sulfate Extended Release Tablets Market Volume (K) By Region

Table 31: Global Morphine Sulfate Extended Release Tablets Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Morphine Sulfate Extended Release Tablets Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Morphine Sulfate Extended Release Tablets Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Morphine Sulfate Extended Release Tablets Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: NAPP PHARMACEUTICALS LIMITED Basic Information And Sales Area

Table 52: NAPP PHARMACEUTICALS LIMITED. Products Portfolio

Table 53: Purdue Pharma Basic Information And Sales Area

Table 54: Purdue Pharma. Products Portfolio

Table 55: Mallinckrodt Pharmaceuticals Basic Information And Sales Area

Table 56: Mallinckrodt Pharmaceuticals. Products Portfolio

Table 57: Teva Pharmaceuticals Basic Information And Sales Area

Table 58: Teva Pharmaceuticals. Products Portfolio

Table 59: Viatris Basic Information And Sales Area

Table 60: Viatris. Products Portfolio

Table 61: Allergan Basic Information And Sales Area

Table 62: Allergan. Products Portfolio

Table 63: Rhodes Pharmaceuticals Basic Information And Sales Area

Table 64: Rhodes Pharmaceuticals. Products Portfolio

Table 65: West-Ward Pharmaceuticals Basic Information And Sales Area

Table 66: West-Ward Pharmaceuticals. Products Portfolio

Table 67: Global Market Value (USD Million) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Value (USD Million) (2025-2032) By Types

Table 70: Global Market Share (%) By Types (2032)

Table 71: Global Market Volume (K) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Volume (K) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Morphine Sulfate Extended Release Tablets Market Value (USD Million) By Region

Table 76: Global Morphine Sulfate Extended Release Tablets Market Share (%) By Region (2025-2032)

Table 77: North America Market Value (USD Million) (2025-2032) By Country

Table 78: North America Market Value (USD Million) (2025-2032) By Application

Table 79: North America Market Value (USD Million) (2025-2032) By Types

Table 80: Europe Market Value (USD Million) (2025-2032) By Country

Table 81: Europe Market Value (USD Million) (2025-2032) By Application

Table 82: Europe Market Value (USD Million) (2025-2032) By Types

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 86: South America Market Value (USD Million) (2025-2032) By Country

Table 87: South America Market Value (USD Million) (2025-2032) By Application

Table 88: South America Market Value (USD Million) (2025-2032) By Types

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 92: Global Morphine Sulfate Extended Release Tablets Market Volume (K) By Region

Table 93: Global Morphine Sulfate Extended Release Tablets Market Share (%) By Region (2025-2032)

Table 94: North America Market Volume (K) (2025-2032) By Country

Table 95: North America Market Volume (K) (2025-2032) By Application

Table 96: North America Market Volume (K) (2025-2032) By Types

Table 97: Europe Market Volume (K) (2025-2032) By Country

Table 98: Europe Market Volume (K) (2025-2032) By Application

Table 99: Europe Market Volume (K) (2025-2032) By Types

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 101: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 103: South America Market Volume (K) (2025-2032) By Country

Table 104: South America Market Volume (K) (2025-2032) By Application

Table 105: South America Market Volume (K) (2025-2032) By Types

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 107: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 109: Research Programs/Design For This Report

Table 110: Key Data Information From Secondary Sources

Table 111: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Morphine Sulfate Extended Release Tablets Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	NAPP PHARMACEUTICALS LIMITED; Purdue Pharma; Mallinckrodt Pharmaceuticals; Teva Pharmaceuticals; Viatris; Allergan; Rhodes Pharmaceuticals; West-Ward Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Intense competition from generic alternatives and non-opioid analgesics is pressuring pricing strategies and profit margins, particularly in markets with cost-sensitive healthcare systems.

Market Segmentation

Loading chart…

Morphine Sulfate Extended Release Tablets Segmentation Breakdown8 items

Application

Hospital

Clinic

Others

Types

10mg

30mg

60mg

Regional Insights

Loading chart…

Regional Market Drivers5 items

North America: Maturing ecosystem maturity, high R&D investments, and robust reimbursement policies.

Europe: Stringent drug safety regulations, aging demographics, and widespread adoption of extended-release analgesics.

Asia Pacific: Expanding healthcare infrastructure, rising disposable incomes, and government initiatives to improve pain management accessibility.

Latin America: Growing awareness of opioid therapies and policy reforms to strengthen pharmaceutical supply chains.

Middle East & Africa: Increasing healthcare infrastructure development and demographic shifts toward urbanization.

Competitive Landscape

NAPP PHARMACEUTICALS LIMITED: regional expansion

Purdue Pharma: innovation pipeline

Mallinckrodt Pharmaceuticals: vertical integration

Teva Pharmaceuticals: OEM tie-ups

Viatris: cost advantages

Allergan: premium pricing

Key Morphine Sulfate Extended Release Tablets Companies8 items

NAPP PHARMACEUTICALS LIMITED

Purdue Pharma

Mallinckrodt Pharmaceuticals

Teva Pharmaceuticals

Viatris

Allergan

Rhodes Pharmaceuticals

West-Ward Pharmaceuticals

Market Ecosystem

Raw material suppliers — Supply APIs and excipients for tablet formulation

Technology providers — Develop controlled-release drug delivery systems and abuse-deterrent mechanisms

API manufacturers — Produce morphine sulfate intermediates for downstream processing

Tablet manufacturers — Execute final formulation, coating, and quality assurance processes

Distributors — Manage product logistics to pharmacies, hospitals, and specialty healthcare providers

Healthcare providers — Prescribe and monitor patient usage through electronic health records

Regulatory bodies — Enforce compliance with FDA/EMA standards for safety and efficacy

Recent Industry Insights

Analyst Overview

Critical Insights3 items

Innovation landscape is dominated by R&D in extended-release technologies and abuse-deterrent mechanisms.

Demand–supply balance remains stable, though raw material volatility and regulatory delays pose intermittent risks.

Key risk factors include opioid policy shifts, litigation pressures, and substitution by non-opioid analgesics.

Table of Contents